A041703
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03739814 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on A041703 (inotuzumab ozogamicin plus blinatumomab; inotuzumab ozogamicin plus blinatumomab plus ponatinib in CD22-positive B-cell acute lymphoblastic leukemia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on A041703 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 9 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration; Bone Marrow Biopsy; Inotuzumab Ozogamicin; Lumbar Puncture; Ponatinib
- Arms
- Cohort 1 (inotuzumab ozogamicin, blinatumomab) · Experimental
- Cohort 2 (inotuzumab ozogamicin, blinatumomab) · Experimental
- Cohort 3 (inotuzumab ozogamicin, blinatumomab, ponatinib)) · Experimental
- Enrollment
- 84 (estimated)
- Primary outcomes
- Event-free survival
- Completion of protocol treatment (cohort 3)
- Sponsor
- National Cancer Institute (NCI)
- Start
- May 8, 2019
- Primary completion
- Feb 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03739814 · updated Oct 28, 2026
Publications
linked from the registry- Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067. PubMed 41671463
- Wieduwilt MJ, Yin J, Kour O, Teske R, Stock W, Escherich C, Yang J, Li Z, Byrd K, Doucette K, Mangan J, Hall S, Mims AS, Jamieson K, Dinner SN, Bseiso AW, Giordano G, Saygin C, Uy GL, Litzow MR, Stone RM. Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results. J Clin Oncol. 2025 Nov 10;43(32):3526-3535. doi: 10.1200/JCO-25-00307. Epub 2025 Sep 30. PubMed 41026957
- Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704. PubMed 35622074